Instil Bio, Inc. (TIL)

NasdaqCM

$7.24+2.84% today

Price as at 1 Oct 2026, 02:35 UTC. Quotes are delayed.

Fundamentals

52-week range$5.67 to $21.98

Valuation and ratings

Instil Bio, Inc. trades at $7.24. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.

About Instil Bio, Inc.

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Industry: BiotechnologyEmployees: 17HQ: United States

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

3 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Common questions

Which funds own TIL?

3 of the institutions we track reported a position in TIL in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.

Where does SteadyShares get its TIL data?

Fundamentals for TIL come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:35 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.

The full research page for TIL, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.

Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.